Search Medical Condition
Please enter condition
Please choose location from dropdown

Blacktown, Australia Clinical Trials

A listing of Blacktown, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (167) clinical trials

A Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a multicenter, open label, dose escalation & expansion phase I study to evaluate the clinical safety, tolerability, PK, and preliminary efficacy of CS3006.

Phase

0.0 miles

Learn More »

A Study to Evaluate the Safety Tolerability and Immunogenicity of V114 Followed by PNEUMOVAX 23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)

This study is designed to 1) describe the safety, tolerability, and immunogenicity of V114 and Prevnar 13 in pneumococcal vaccine-nave adults at increased risk for pneumococcal disease and to 2) describe the safety, tolerability, and immunogenicity of PNEUMOVAX23 when administered 6 months after receipt of either V114 or Prevnar 13. ...

Phase

0.0 miles

Learn More »

Point-of-Care Immunoassay for Detection of Bacterial Sinusitis

Mucous specimens will be collected from patients displaying symptoms of acute bacterial sinusitis enrolled by primary care and/or otolaryngology clinics in the United States and Australia. Health care professionals not having endoscopy certification will collect specimens using the Entvantage sample collection device. Health care professionals with nasal endoscopy certification or ...

Phase N/A

0.0 miles

Learn More »

A Study to Explore the Antiviral Activity Clinical Outcomes Safety Tolerability and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus

This study will be performed to explore the antiviral activity, clinical outcomes, safety, tolerability, and pharmacokinetics of JNJ-53718678 in adult participants infected with RSV. The study will include both participants who are otherwise healthy (ie, without underlying condition) or who have comorbid conditions (eg, asthma, chronic obstructive pulmonary disease (COPD), ...

Phase

0.75 miles

Learn More »

Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486

MDS is an insidious and largely incurable haematological malignancy that increasingly impacts on the well-being of our ageing population, and one for which there has been no significant therapeutic advance since the introduction of injectable AZA (Vidaza) over a decade ago. Furthermore, the basis for the effectiveness of Vidaza or ...

Phase

1.0 miles

Learn More »

An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

The purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab in patients with cancers that are advanced or have spread. Pharmacokinetics and pharmacodynamics of BMS-986205 when combined with Nivolumab and in combination with ...

Phase

3.23 miles

Learn More »

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

This is a Phase 1b/2, open-label, multi-center, multiple-dose, safety, clinical activity, PK, and PD study of avelumab in combination with other immune modulators in adult patients with locally advanced or metastatic solid tumors (eg, non-small cell lung cancer (NSCLC), melanoma, squamous cell carcinoma of the head and neck (SCCHN), triple-negative ...

Phase

3.6 miles

Learn More »

Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A New Causes of CMT2

This project is to understand modifier genes and how they influence the severity of disease expression, along with identifying new forms of CMT which have not been genetically determined. Subjects who are eligible will either have CMT type 1A (CMT1A) or an unknown form of CMT. Blood will be drawn ...

Phase N/A

4.01 miles

Learn More »

Neoadjuvant Dabrafenib Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma

The new drug options for advanced melanoma include oncogene-targeted therapy (such as dabrafenib, trametinib and vemurafenib) and immune checkpoint blockade (such as pembrolizumab, nivolumab and ipilimumab). These drugs have shown remarkable efficacy and have regulatory approval for metastatic disease. However, most patients with advanced disease eventually progress. It is unknown ...

Phase

4.01 miles

Learn More »

Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation

The study will analyse the safety and biological efficacy of administering the investigational products (most closely HLA-matched third party donor-derived T cells stimulated with viral or fungal antigen expressing DC), for the treatment of viral reactivation and/or infection or fungal infection following allogeneic blood or marrow or solid organ transplantation. ...

Phase

4.01 miles

Learn More »